866-997-4948(US-Canada Toll Free)

Myeloma Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

Published By :

GBI Research

Published Date : Oct 2015

Category :

Therapeutic Area

No. of Pages : N/A

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. The disease is incurable; although over the past decade there have been significant improvements in therapy, driven by a greater understanding of pathophysiology. MM represents about 0.8

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Etiology 10
2.3 Pathophysiology 11
2.4 Symptoms 12
2.5 Diagnosis and Classification 12
2.6 Epidemiology 15
2.7 Prognosis and Disease Staging 16
2.8 Treatment Options 18
2.8.1 Treatment Algorithm 20
2.8.2 Initial Therapy for Newly Diagnosed Symptomatic Disease 20
2.8.3 Maintenance Therapy 25
2.8.4 Therapy for Relapsed or Refractory Myeloma 26

3 Marketed Products 32
3.1 Overview 32
3.2 Immunomodulatory Agents 32
3.2.1 Thalomid (thalidomide) – Celgene 32
3.2.2 Revlimid (lenalidomide) – Celgene 33
3.2.3 Pomalyst (pomalidomide) – Celgene 33
3.3 Proteasome Inhibitors 34
3.3.1 Velcade (bortezomib) – Millennium Pharmaceuticals/Takeda 34
3.3.2 Kyprolis (carfilzomib) – Onyx 34
3.4 Histone Deacetylase Inhibitors 35
3.4.1 Farydak (panobinostat) – Novartis 35
3.5 Chemotherapy 36
3.5.1 Doxil (doxorubicin HCl liposome injection) – Janssen 36
3.6 Comparative Efficacy and Safety of Marketed Products 36

4 Pipeline Products 40
4.1 Overall Pipeline 40
4.2 Pipeline Analysis by Molecular Target 41

5 Clinical Trials 45
5.1 Failure Rate 45
5.2 Patient Enrolment and Clinical Trial Size 47
5.3 Duration 53
5.4 Competitive Clinical Trials Metrics Analysis 57
5.5 Promising Drug Candidates in the Pipeline 58
5.5.1 Daratumumab – Johnson & Johnson 58
5.5.2 Elotuzumab – AbbVie and Bristol Myers Squibb 59
5.5.3 Ixazomib – Millennium Pharmaceuticals 60
5.5.4 Zolinza (vorinostat) – Merck 62
5.5.5 ARRY-520 (filanesib) – Array Biopharma 63
5.5.6 Aplidin (plitidepsin) – PharmaMar 64
5.6 Heat Map for Pipeline Products 65

6 Market Forecast to 2021 67
6.1 Geographical Markets 67
6.2 Asia-Pacific Market 68
6.3 India 69
6.3.1 Treatment Usage Patterns 69
6.3.2 Annual Cost of Therapy 70
6.3.3 Market Size 70
6.4 China 71
6.4.1 Treatment Usage Patterns 71
6.4.2 Annual Cost of Therapy 72
6.4.3 Market Size 73
6.5 Australia 73
6.5.1 Treatment Usage Patterns 73
6.5.2 Annual Cost of Therapy 74
6.5.3 Market Size 75
6.6 Japan 76
6.6.1 Treatment Usage Patterns 76
6.6.2 Annual Cost of Therapy 77
6.6.3 Market Size 78

7 Drivers and Barriers for the Disease Market 79
7.1 Drivers 79
7.1.1 Rising Prevalence 79
7.1.2 Increasing Therapeutic Options 79
7.1.3 Limited Generic Competition 79
7.2 Barriers 79
7.2.1 Limited Target Patient Population 79
7.2.2 Large Undiagnosed Pool 80
7.2.3 Lower Usage of Costlier Therapies in India and China 80
7.2.4 Costly Drug Development 80

8 Deals and Strategic Consolidations 81
8.1 Licensing Deals 81
8.1.1 PharmaMar Announces Licensing Agreement with TTY Biopharm for Aplidin in Hematological Cancers 87
8.1.2 Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 87
8.1.3 Genentech Enters into Licensing Agreement with Seattle Genetics – Now Terminated 88
8.1.4 OncoPep Enters into Licensing Agreement with Dana-Farber Cancer Institute for Cancer Vaccine Technology 88
8.1.5 PharmaMar Enters into Licensing Agreement with Chugai for Aplidin 88
8.1.6 Onyx Enters into Licensing Agreement with Ono Pharma for Kyprolis and Oprozomib 88
8.2 Co-development Deals 89
8.2.1 Celgene Enters into Co-development Agreement with MedImmune 93
8.2.2 Acetylon Enters into Co-development Agreement with Leukemia & Lymphoma Society 93
8.2.3 Boehringer Ingelheim Enters into Collaboration Agreement with Micromet 94
8.2.4 Multiple Myeloma Research Foundation Enters into Co-development Agreement with Onyx 94
8.2.5 Dana-Farber Cancer Institute Enters into Agreement with MannKind 94
8.2.6 Nordic Nanovector Enters into Co-development Agreement with Affibody 94

9 Appendix 95
9.1 All Pipeline Drugs by Phase of Development 95
9.1.1 Discovery 95
9.1.2 Preclinical 97
9.1.3 Investigational New Drug/Clinical Trial Application-Filed 100
9.1.4 Phase I 101
9.1.5 Phase II 104
9.1.6 Phase III 107
9.1.7 Pre-registration 107
9.2 Market Forecasts to 2021 108
9.2.1 Asia-Pacific 108
9.2.2 India 108
9.2.3 China 109
9.2.4 Australia 109
9.2.5 Japan 110
9.3 Bibliography 110
9.4 Research Methodology 116
9.4.1 Secondary Research 117
9.4.2 Marketed Product Profiles 117
9.4.3 Late-Stage Pipeline Candidates 117
9.4.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 117
9.4.5 Forecasting Model 118
9.4.6 Deals Data Analysis 119
9.5 Expert Panel Validation 120
9.6 Contact Us 120
9.7 Disclaimer 120

List of Table

Table 1: Multiple Myeloma Therapeutics Market, Initial Screening in Suspected Myeloma Patients 13
Table 2: Multiple Myeloma Therapeutics Market, Diagnostic Criteria for MGUS, Asymptomatic Myeloma and Symptomatic Myeloma 14
Table 3: Multiple Myeloma Therapeutics Market, Myeloma-Related Organ or Tissue Impairment 14
Table 4: Multiple Myeloma Therapeutics Market, Disease Staging, Durie-Salmon Staging System 16
Table 5: Multiple Myeloma Therapeutics Market, Prognostic Factors 18
Table 6: Multiple Myeloma Therapeutics Market, Prognostic Factors 19
Table 7: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Discovery, 2015 95
Table 8: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Preclinical, 2015 97
Table 9: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015 100
Table 10: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase I, 2015 101
Table 11: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase II, 2015 104
Table 12: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Phase III, 2015 107
Table 13: Multiple Myeloma Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015 107
Table 14: Multiple Myeloma Therapeutics Market, Asia-Pacific, Market Forecast, 2014–2021 108
Table 15: Multiple Myeloma Therapeutics Market, India, Market Forecast, 2014–2021 108
Table 16: Multiple Myeloma Therapeutics Market, China, Market Forecast, 2014–2021 109
Table 17: Multiple Myeloma Therapeutics Market, Australia, Market Forecast, 2014–2021 109
Table 18: Multiple Myeloma Therapeutics Market, Japan, Market Forecast, 2014–2021 110

List of Chart


Figure 1: Multiple Myeloma Therapeutics Market, Australia, Age-Specific Incidence Rate and Average Number of Cases, 2007–2011 15
Figure 2: Multiple Myeloma Therapeutics Market, Treatment Algorithm for Myeloma 20
Figure 3: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment – Efficacy 37
Figure 4: Multiple Myeloma Therapeutics Market, Global, Heat Map for Initial Treatment – Safety 38
Figure 5: Multiple Myeloma Therapeutics Market, Global, Heat Map for Maintenance Treatment 38
Figure 6: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma – Efficacy 38
Figure 7: Multiple Myeloma Therapeutics Market, Global, Heat Map for Relapsed or Refractory Multiple Myeloma – Safety 39
Figure 8: Multiple Myeloma Therapeutics Market, Global, Overview of Pipeline Products 41
Figure 9: Multiple Myeloma Therapeutics Market, Global, Target Families in Pipeline 44
Figure 10: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase (%), 2006–2015 45
Figure 11: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type (%), 2006–2015 46
Figure 12: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target (%), 2006–2015 47
Figure 13: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2015 48
Figure 14: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006–2015 49
Figure 15: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006–2015 51
Figure 16: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006–2015 52
Figure 17: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2015 54
Figure 18: Multiple Myeloma Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2015 56
Figure 19: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 57
Figure 20: Multiple Myeloma Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 58
Figure 21: Multiple Myeloma Therapeutics Market, Global, Pipeline Heat Map, 2015 65
Figure 22: Multiple Myeloma Therapeutics Market, Asia-Pacific, Treatment Patterns (‘000) and Market Size ($bn), 2014–2021 68
Figure 23: Multiple Myeloma Therapeutics Market, India, Treatment Patterns (‘000), 2014–2021 69
Figure 24: Multiple Myeloma Therapeutics Market, India, Annual Cost of Therapy ($), 2014–2021 70
Figure 25: Multiple Myeloma Therapeutics Market, India, Market Size ($m), 2014–2021 71
Figure 26: Multiple Myeloma Therapeutics Market, China, Treatment Patterns (‘000), 2014–2021 72
Figure 27: Multiple Myeloma Therapeutics Market, China, Annual Cost of Therapy ($), 2014–2021 72
Figure 28: Multiple Myeloma Therapeutics Market, China, Market Size ($m), 2014–2021 73
Figure 29: Multiple Myeloma Market, Australia, Treatment Usage Patterns (‘000), 2014–2021 74
Figure 30: Multiple Myeloma Market, Australia, Annual Cost of Therapy ($), 2014–2021 74
Figure 31: Multiple Myeloma Therapeutics Market, Australia, Market Size ($m), 2014–2021 75
Figure 32: Multiple Myeloma Market, Japan, Treatment Usage Patterns (‘000), 2014–2021 76
Figure 33: Multiple Myeloma Market, Japan, Annual Cost of Therapy ($), 2014–2021 77
Figure 34: Multiple Myeloma Therapeutics Market, Japan, Market Size ($m), 2014–2021 78
Figure 35: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Region, 2006–2015 81
Figure 36: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Deal Value ($m), 2006–2015 82
Figure 37: Multiple Myeloma Therapeutics Market, Global, Number of Deals and Aggregate Deal Value ($m), 2006–2015 83
Figure 38: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006–2015 84
Figure 39: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006–2015 85
Figure 40: Multiple Myeloma Therapeutics Market, Global, Licensing Deals by Molecular Target, 2006–2015 87
Figure 41: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Region, 2006–2015 89
Figure 42: Multiple Myeloma Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, 2006–2015 90
Figure 43: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006–2015 91
Figure 44: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006–2015 92
Figure 45: Multiple Myeloma Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006–2015 93

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *